Category Archive slider

Megaflora 9 evo: Clinical evidence

Two separate pilot studies have determined the in vivo survival of Megaflora 9 evo bacteria.

Survival of Bifidobacterium

In the first study, the survival of Bifidobacterium was tested in 23 medical students from the University of Wageningen. The study was randomized double-blind controlled versus placebo with a dosage of 4 g of Megaflora 9 evo or placebo per day divided in 2 doses for 7 days.

At the beginning and at the end of the study stool samples were analyzed by PCR, DGGE and FISH. The results showed that students who consumed Megaflora 9 evo presented a clear difference in the population of bifidobacteria in the faeces compared to the placebo group, evidenced by the DGGE profile.

The image shows the DGGE results of nine students, 6 consuming Megaflora 9 evo (M9E) and 3 consuming placebo (P). It can be appreciated that students M9E-1 and M9E-7 presented specific markers for bifidobacteria at day 7 after consumption of Megaflora 9 evo compared with baseline (red circles).

Profile DGGE to identify the presence of bifidobacteria in faecal samples from students at baseline and 7 days of consuming Megaflora 9 evo or placebo. Red circles show clear differences in the presence of markers in bifidobacteria group students Megaflora 9 evo.

These results demonstrate the survival of Bifidobacterium of Megaflora 9 evo in the gastrointestinal tract.

Survival of Lactobacillus

In the second study, 100 medical students from the University of Maastricht participated in a randomized double-blind controlled study versus placebo. The students were equally divided into two groups that were given Megaflora 9 evo or placebo.

The duration of the study was 8 days during which students consumed a dose of 3.8 g of Megaflora 9 evo or placebo divided by 2 times a day. The aim of the study was to check the survival of lactobacilli present in the faeces after ingestion.

The result showed a significant difference of lactobacilli in the faeces of students who consumed Megaflora 9 evo, demonstrating the survival of the bacteria after the GI passage.

Results of the clinical study in 100 medical students on the survival of lactobacilli. Department of Microbiology at the University of Maastricht

Key points

Megaflora 9 evo is a unique product in its category as it is the result of the development and research that has been carried out to obtain a composition that has a broad spectrum of application:

  • It is based on the concept of multi-strain and multi-species.
  • It has a 4 year stability at room temperature (25° C).
  • It has a high survival in the gastrointestinal tract.
  • It has a high metabolic activity of lactic acid production.
  • It is able to inhibit the growth of pathogenic flora (Clostridium, Candida, E. coli, S. aureus, Salmonella, etc.).
  • It is able to maintain the barrier effect protecting the intestinal epithelium against damage from external agents.
  • It is able to stimulate the production of IL-10 to influence by both mechanisms immunomodulation.

In addition Megaflora 9 evo present also these features:

  • Convenient dosage of 1 to 2 g per day.
  • Total solubility in water, milk and yogurt.
  • Safe consumption: allergen free including gluten-free and it may be recommended from 1 year of baby life.